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Background: Calreticulin (CRT) is a chaperone protein, which aids correct folding of glycosylated proteins in the
endoplasmic reticulum (ER). Under conditions of ER stress, CRT is upregulated and may be displayed on the surface
of cells or be secreted. This ‘ecto-CRT’ may activate the innate immune response or it may aid clearance of
apoptotic cells. Our and other studies have demonstrated upregulation of ER stress markers CHOP, BiP, ATF4, XBP1
and phosphorylated e-IF2 alpha (p-eIF2 alpha) in biopsy and post-mortem human multiple sclerosis (MS) samples.
We extend this work by analysing changes in expression of CRT, BiP, CHOP, XBP1 and p-eIF2 alpha in a rat model
of inflammatory demyelination. Demyelination was induced in the spinal cord by intradermal injection of
recombinant mouse MOG mixed with incomplete Freund’s adjuvant (IFA) at the base of the tail. Tissue samples
were analysed by semi-quantitative scoring of immunohistochemically stained frozen tissue sections. Data
generated following sampling of tissue from animals with spinal cord lesions, was compared to that obtained using
tissue derived from IFA- or saline-injected controls. CRT present in rat serum and in a cohort of human serum
derived from 14 multiple sclerosis patients and 11 healthy controls was measured by ELISA.
Results: Stained tissue scores revealed significantly (p<0.05) increased amounts of CRT, CHOP and p-eIF2 alpha in
the lesion, lesion edge and normal-appearing white matter when compared to controls. CHOP and p-eIF2 alpha
were also significantly raised in regions of grey matter and the central canal (p<0.05). Immunofluorescent dual-label
staining confirmed expression of these markers in astrocytes, microglia or neurons. Dual staining of rat and human
spinal cord lesions with Oil Red O and CRT antibody showed co-localisation of CRT with the rim of myelin
fragments. ELISA testing of sera from control and EAE rats demonstrated significant down-regulation (p<0.05) of
CRT in the serum of EAE animals, compared to saline and IFA controls. This contrasted with significantly increased
amounts of CRT detected in the sera of MS patients (p<0.05), compared to controls.
Conclusion: This data highlights the potential importance of CRT and other ER stress proteins in inflammatory
demyelination.
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Proteins associated with endoplasmic reticulum (ER)
stress have recently been shown in human demyelin-
ating lesions in central nervous system white and grey
matter [1-4]. Homeostasis within the ER is of great
importance as it is the site of synthesis and folding of
approximately one third of all mammalian proteins
i.e., those which are targeted to membranes or for se-
cretion. The ER also plays a central role in lipid syn-
thesis and is the major site of calcium storage within
the cell. However, a range of pathologies may cause
the break-down of protein-folding mechanisms,
resulting in a cellular response called the ‘unfolded
protein response’ (UPR) or ‘ER stress’ [5].Triggered
initially when the ER chaperone GRP78/BiP detaches
from ER trans-membrane sensors pancreatic PKR-like
ER kinase (PERK), inositol-requiring enzyme 1 (IRE1) and
activating transcription factor 6 (ATF6), the UPR tempor-
arily halts protein translation, degrades mis-folded
proteins and newly synthesises ER chaperones to restore
normal protein folding. Detection of raised levels of
Grp78 / BiP, X-box-binding factor 1 (XBP1), phosphorylated
PERK (p-PERK), phosphorylated IRE1 (p-Ire1) or
phosphorylated eukaryotic initiation factor alpha
(p-eIF2α) is indicative of an active ‘protective’ ER stress
response. On the other hand, increased expression of
transcription factor CHOP is widely considered to in-
dicate that cells may have activated a pro-apoptotic
response following the failure to restore normal ER
function [6].
Calreticulin (CRT) is a molecular chaperone nor-
mally associated with the CRT-calnexin glycoprotein-
folding machinery and calcium binding within the ER
[7]. However, there is an increasingly diverse array of
physiological and pathological functions now associ-
ated with cell surface or secreted CRT [8,9]. For ex-
ample, cell surface CRT has a putative role in the
clearance of apoptotic cells [10,11] and in the activa-
tion of the innate immune response [12,13]. The fact
that it is induced following ER stress and the
reported link between CRT and autoimmunity, in the
context of rheumatoid arthritis [14], prompted us to
examine the expression of CRT and other markers of
ER stress in an experimental autoimmune encephalo-
myelitis (EAE) model of spinal cord demyelination.
Pathology was induced in Dark Agouti (DA) rats in
response to intradermal injection of recombinant
mouse myelin oligodendrocyte glycoprotein (rmMOG)
and the expression of CHOP, BiP, p-eIF2α, XBP1 and
CRT examined. Levels of circulating CRT in the sera
of diseased rats and in MS patient sera were also
quantified. The potential relevance of CRT and other
ER stress marker protein expression in the develop-
ment of a demyelinating phenotype is discussed.Results
Significant up-regulation of protein markers of ER stress
in demyelinating white matter
Immunohistochemical staining confirmed a significantly
higher degree of expression of CRT, CHOP, XBP1 and
p-eIF2α within demyelinating lesions, when compared
to normal IFA- and saline-injected controls (Figure 1). CRT
achieved a semi-quantitative score of 4.3 ± 0.4 arbitrary
units (AU), in lesion centres, against scores of 0.7 AU
(± 0.1-0.2, p<0.01) in the NAWM of IFA- or saline-injected
animals. The CRT score dropped slightly (not significant)
to 3 AU at the lesion edge. Sample low-magnification
images of CRT-stained control and experimental tissue are
shown in Figure 2a and 2b. Morphological criteria applied
to single chromogenic labelling suggested that different
proportions of a range of cell types were expressing
CRT (Figure 2b, c and d). This was confirmed by
dual immunofluorescent labelling of astrocytes and
microglia (Figure 2g-k). Double-staining of myelin
fragments and CRT demonstrated that in some areas
of lesioned tissue, CRT was colocalising with the lipid
rim (Figure 2f ).
In contrast to CRT, monitoring of changes in BiP
expression within different tissue regions yielded no
significant results (Figure 1).
When staining for transcription factor CHOP was car-
ried out (see Figure 3a and 3b), it revealed significantly
higher (p<0.001) expression in the lesion (3.9 AU ± 0.2)
and lesion edge (3.9 ± 0.1), when compared to saline
(0.8 ± 0.1) or IFA (0.9 ± 0.2) -injected controls
(Figure 1). Tissue stained for XBP1 (see Figure 3g and
3h) had a slightly lower profile of expression, scoring
3.5 ± 0.4 within lesions, rising to 3.8 ± 0.6 at the lesion
edge, values which were significantly different (p<0.05)
to those calculated for saline controls, but not those
obtained when IFA controls were analysed. Represen-
tative images of tissue stained with CHOP and
XBP1antibodies are provided in Figure 3a -3h. Again,
morphological criteria suggest that a variety of cell
types express these transcription factors (see Figure 3c,
d, h), which, in the case of CHOP, was confirmed by
CHOP-IBA1 dual labelling (Figure 3d, e).
Finally, immunohistochemical analysis of expres-
sion of p-eIF2α provided confirmation that the PERK
arm of the ER stress response was activated in dis-
eased WM of the spinal cord. Semi-quantitative
scores were slightly lower than those seen for the
other markers tested, at 3.1 ± 0.3 (lesion) or 3.0 ±
0.4 at the lesion edge. Lesion edge scores differed
significantly from those recorded for IFA (0.7 ± 0.2,
p<0.05) and saline (0.5 ± 0, p<0.05) controls, while
the lesion scores differed significantly from the saline
controls only (p<0.05). Staining of a variety of cell types
was clearly evident (Figure 4b) and expression in microglia
Figure 1 Quantification of up-regulation of protein markers of ER stress in spinal cord EAE lesions. Semi-quantitatitive analysis of the
spinal cord white matter EAE lesions and lesion edges revealed a trend towards upregulation of BiP, compared to IFA and saline controls (a).
Scores for CRT (b), CHOP (c) and p-eIF2α (e) were significantly higher within lesions and the NAWM than those measured in the NAWM of IFA
samples. Significant upregulation of CRT, CHOP, XBP1 (d) and p-eIF2α, was found in EAE lesions and NAWM, when compared to saline controls.
Key: * = p<0.05; ** = p<0.01; *** = p<0.001. Data is represented as mean arbitrary units (AU) ± SEM.
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(Figure 4c-e).
Monitoring of NAWM staining patterns showed that
in all cases, protein expression was lower than that seen
in the lesion edge and centre. In the case of CRT (1.7 ±
0.5), CHOP (2.2 ± 0.4) and p-eIF2α expression levels dif-
fered significantly (p<0.01 or 0.05) from those seen in
IFA controls, whereas expression of XBP1 (2.1± 0.3) sig-
nificantly differed (p<0.05) from that seen in saline con-
trols only.
Significant up-regulation of protein markers of ER stress
in grey matter and central canal of the spinal cord
Expression of BiP, CRT, CHOP, XBP1 and p-eIF2α was next
examined in the grey matter (GM). Intense staining ofmotoneurons of the ventral horn by anti-BiP and anti-CRT
antibodies was obtained (scoring between 2 and 3), but
there was no significant difference in numbers of positively
stained cells, when control and experimental tissue was
compared (Figure 5). However, significantly increased ex-
pression of CHOP (2.6 ± 0.4, p<0.05) was detected, when
compared to IFA (0.8 ± 0.2) and saline (0.8 ± 0.3) control
specimens. The XBP1 scores (3.1 ± 1.6) differed
significantly from those recorded for saline-injected
samples (1.1 ± 0.5, p<0.05), differences were not
significant when comparisons were made with IFA
tissue (Figure 5).
The intensity of chromogenic staining of neurons for
p-eIF2α, was consistently higher than that obtained in
IFA controls (bottom panels Figure 5) and was lower
Figure 2 CRT staining in spinal cord EAE lesions. There was little or no CRT expressed in IFA-injected spinal cords (a) compared to EAE lesions
(b). At increased magnification, CRT staining was evident in a number of cell types, morphologically resembling astrocytes (c) and macrophages
(d). CRT was expressed in Oil Red O deposits (f and digitally zoomed inset). ORO deposits colocalising with CRT were absent from IFA control spinal
cord tissue (e). Fluorescent dual-labelled images (g-i) show CRT (red) expression in astrocytes (GFAP, green), as well as macrophage/microglia (Iba1+,
green, k). Confocal analysis demonstrated punctate staining of CRT in microglia (j). Scale bars = 60 μm (g-i), 50 μm (a-b,e-f,j-k), 20 μm (c-d).
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proportion of cells which stained positively was also
lower, a fact reflected in the lower scores of 1.9 ± 0.4
obtained. Nonetheless, these scores were found to differ
significantly from levels found in controls which yielded
0.7 ± 0.1 (IFA, p<0.05) or 0.5 ± 0 (saline, p<0.01). Dual
immunofluorescent labelling of neurons confirmed co-
expression of CHOP (Additional file 1).Semi-quanitative scoring of staining of the central canal
(Figure 6), identified significantly increased expression
of CHOP (3.6 ± 0.6, p<0.05), XBP1 (3.4 ± 0.4, p<0.01)
and p-eIF2α (2.3 ± 0.6, p<0.05), when compared to the
same proteins in the central canal of IFA samples
(CHOP, 1.1 ± 0.3; XBP1, 1.4 ± 0.5; p-eIF2α, 0.2 ± 0.1)
or tissue from saline controls (CHOP, 1.0 ± 0.2; XBP1,
0.5 ± 0; p-eIF2α, 0.6 ± 0.1).
Figure 3 Immunohistochemical staining of CHOP and XBP1 expression in spinal cord EAE lesions. CHOP and XBP1 were positively
expressed in spinal cord EAE lesions (b & g, respectively) but were minimal or absent in IFA control tissue (a & f). At a higher magnification (h),
clear positive/nuclear staining of cells with morphological ‘street-like’ features of oligodendrcoytes is present. A ventro-lateral white matter lesion
dual-labelled using antibodies to SMI32, NeuN and CHOP shows a large number of CHOP-positive cells with features consistent with microglia/
macrophages within the lesion centre (d). Co-localisation of CHOP in macrophage/microglia was confirmed (see ‘e’) by dual immunofluorescence
(Iba1+/green, CHOP/red). Scale bars = 100 μm (d), 50 μm (a-c; e, f-g), 20 μm (h).
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serum of EAE animals and is significantly increased in the
serum of individuals with MS
Levels of CRT in the serum of EAE animals were
analysed by ELISA and compared to values generated by
control IFA and saline rats. The 244 ± 21 ng/ml of CRT
detected in EAE sera was significantly lower than the
308 – 347 ±18-20 ng/ml found in IFA (p<0.05) or saline
(p<0.01) controls (Figure 7a). A significant difference
(p<0.05) in the opposite direction was determined when
serum samples from 14 individuals suffering from MS
were compared to samples taken from 11 non-neurological
controls (Figure 7b). That is, a mean level of 428 (± 40)
ng/ml was detected in persons with MS (n=14), which
was 28% higher than the average 335 (± 17) ng/ml seenin controls (n=11). It is worth noting that none of the
MS patients were on steroids at the time of sampling
and that in all cases it had been at least 5 months since
the last relapse (with the exception of one individual,
for whom this information was not available).When data
generated by individuals with MS is sub-divided into two
groups (Figure 7c), depending on whether or not patients
were on Natalizumab, mean CRT levels were lower in
Natalizumab-treated patients (382 ± 48 ng/ml, n=9) than
in those who were not on Natalizumab (512 ± 67 ng/ml,
n=5). Moreover, the mean value for Natalizumab-treated
patients was still higher, but no longer differed significantly
from healthy control CRT levels, while significant differ-
ences (p<0.05) were retained between non-Natalizumab
samples and controls (Figure 7c).
Figure 4 Profile of expression of p-eIF2αin spinal cord EAE lesions. p-eIF2α was expressed in spinal cord EAE lesions (b) at an increased
level compared to IFA control tissue (a). Dual immunofluorescence (asterisk, arrows, CD68 / green, CHOP red) demonstrated that p-eIF2α (green)
was expressed in macrophages (c-e). Scale bars = 50 μm (a-b), 10 μm (c-e).
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The chief outcomes from this study have been the demon-
stration for the first time that: (i) following MOG-induced
spinal cord demyelination in the DA rat, CRT, CHOP and
p-EIF2α were present at significantly increased levels within
spinal cord lesions; (ii) significantly increased amounts of
CRT, CHOP, XBP1 and p-eIF2α were detectable in the re-
gion of the central canal of diseased animals; (iii) levels of
circulating CRT were significantly lower in EAE rat sera,
when compared to control samples; (iv) CRT in human
blood sera was present at significantly higher levels in indi-
viduals with MS, than in healthy controls.
Using intradermal injection of rmMOG, demyelination
was induced in the spinal cord of adult female DA rats.
Control animals were injected with IFA or saline only.
Nine out of 10 animals developed a phenotype 13–21 days
post MOG injection, which was retained in 5 individuals
on the day of tissue harvesting. Inflammatory myelin loss
was identified by staining of myelin and infiltrating micro-
glia and the presence of myelin fragments within lesions
was confirmed using ORO staining. After isolation of
total RNA from whole spinal cord lysates, real-time
PCR analysis of ER stress-related transcripts did not
detect significant differences between control and EAE
samples. A semi-quantitative protocol was then applied to
immunohistochemically-stained tissue from the 5 rats in
which inflammatory pathology was confirmed. On a scale
of 1 to 5, the degree of staining was scored within the
lesion, lesion edge, NAWM, GM and the region of the
central canal and compared to that generated using IFAand saline controls. A total of 240 experimental and con-
trol tissue sections were examined, enabling us to profile
the expression of BiP, CRT, CHOP, XBP1 and p-eIF2α.
At significantly increased scores, ranging from 1.6 to
5 in all EAE-associated regions examined, CRT was
detected in astrocytes, microglia and GM neurons.
When present, oligodendrocyte expression of CRT was
minimal (not shown). IFA and saline control samples
achieved CRT scores of 1 or less. An intriguing finding
was the localisation of CRT to the rim of ORO-positive
myelin fragments (confirmed in a human MS tissue
sample, see additional file 2) and the punctate or ‘patchy’
nature of CRT staining seen when tissue was dual-labelled
with CRT and GFAP or IBA1 (Figure 4i and j).
In contrast to CRT, we were unable to detect significant
changes in the proportion of BiP-positive cells, when con-
trol and EAE samples were analysed. However, with scores
of 2.2 to 3.9 AU, compared to staining in saline and IFA
sections, which yielded scores of 1 or less, dual-labelling
confirmed CHOP expression in astrocytes and microglia.
Positive staining for XBP1, which scored 2.1 to 3.5,
could be seen in a range of cell types within WM lesions
following chromogenic single labelling, but the level of
staining differed significantly only from the pattern seen
in saline controls.
The final marker of ER stress assessed was p-eIF2α.
Following tissue staining, it yielded scores of 1.9 to
3.1 AU. When morphological criteria were applied to the
pattern of chromogenic staining seen, p-eIF2α staining
appeared to be present in a range of cell types. Dual
Figure 5 Upregulation of ER stress molecules in spinal cord grey matter neurons. Semi-quantitative analysis of ER stress molecule
expression in neurons of the grey matter showed an upward trend in BiP and CRT expression, when compared to control IFA or saline groups.
CHOP, XBP1 and p-eIF2α scores differed significantly from saline controls, while staining of CHOP and p-eIF2α protein also differed significantly
from the pattern seen in IFA controls. Histogram data (RH panels) is represented as semi-quantitative immunostaining score / mean arbitrary
units (AU)±SEM, n = 5 for all scores. Key: * = p<0.05. Representative images of staining of the grey matter in IFA controls (LH panels) and EAE
samples (middle panels), is shown. Scale bars = 50 μm.
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p-eIF2α within lesions, at the lesion edge, in GM and the
CC was also significantly higher than levels recorded for
equivalent areas in saline and IFA controls.
Results obtained when NAWM was examined hinted
that CRT, CHOP and p-eIF2α could be involved in
lesion development, as these markers were present at
significantly higher levels when compared to control
counterparts.
Detection of significantly higher levels of CHOP and
phospho-eIF2α within the region of the central canal in
diseased animals hints that possible triggers of ER stress
may be present in the cerebrospinal fluid and an inves-
tigation of candidate molecules is warranted.We then expanded our investigations to include analysis
of CRT secretion into the blood of EAE rats and in samples
drawn from a cohort of 14 individuals with MS and 11
healthy controls. Data showed significantly reduced levels
of CRT in rat sera when compared to IFA or saline control
animals. The reverse was seen when human samples were
analysed, in that MS patient samples contained significantly
higher levels of secreted CRT. When results generated
using samples taken from Natalizumab-treated patients
only were analysed separately, mean CRT values were not
found to differ significantly from mean values in healthy
individuals. In contrast, the amounts of CRT detected in
serum from individuals not undergoing treatment with
Natalizumab, remained significantly higher than controls.
Figure 6 Upregulation of ER stress molecules in the spinal cord central canal region. Semiquantitative analysis of the cells of the central
canal (RH panel) showed a trend towards upregulation of the ER stress chaperones BiP and CRT when compared to control animals but these
differences did not reach significance. Significant upregulation of CHOP, XBP1 and p-eIF2α was detected when EAE and saline samples were
compared. CHOP and p-eIF2α values were significantly different to those seen in IFA controls. Representative images of staining in IFA control
spinal cord tissue (LH panels) and in EAE lesions (middle panels) are shown. Magnified images of cells positively stained for CHOP (inset, RH middle
panel) and p-eIF2a (inset, bottom middle panel) show cuboidal morphology consistent with ependymal cells. Histogram data is represented as
semi-quantitative immunostaining score / mean arbitrary units (AU)±SEM, n = 5 for all scores except XBP1, where n = 4 for EAE-treated animals and
n = 3 for CRT stained section in saline control group. Key: *=p<0.05; **p<0.01. Scale bars = 50 μm.
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models. However, in broad terms, the data we have
generated in rats confirms and adds to findings pub-
lished using SJL and C57Bl/6 mice, in that BiP, CHOP,
XBP1 and p-eIF2α were reported as significantly altered in
these models [15-19] The question of what individual ER
stress proteins are doing in the context of demyelination
has yet to be answered. Deslauriers et al. [17] showed that
EAE occured to the same degree in CHOP-/- mice as in
normal controls, suggesting that CHOP is not required to
induce inflammatory demyelination in mice. When present,
as in our rat model, CHOP may be involved in perpetuatingpro-apoptotic signals leading to loss of CHOP-positive cells
within lesions. Alternatively, Popko and colleagues have
proposed that CHOP is not pro-apoptotic, but is uniquely
required to achieve complete remyelination following
inflammatory demyelination [20].
The second major transcription factor associated with
ER stress is XBP1. We found this highly specific marker
of ER stress to be significantly altered in all regions of
EAE lesions and in NAWM, when compared to saline-
injected controls, but levels of XBP1 in EAE lesions did
not differ significantly from those detected in control
IFA animals. This is at odds with reported significant
Figure 7 Quantification of circulating CRT in rat and human sera. Levels of CRT in rat sera (a) were measured by ELISA, revealing that CRT in
EAE animals (n=5) was significantly (p<0.05) less than that in control animals (n=5). Testing for CRT in human sera (b) revealed significantly
increased CRT in human MS sera (p<0.05), n=14) when compared to healthy controls (n=11). When data from MS samples was separated (c)
according to whether or not individuals were undergoing treatment with nataluzimab, CRT was still significantly higher (p<0.01) in non-
nataluzimab-treated patients (n=5), compared to samples from healthy controls (n=11). There was no significant difference in levels found in
individuals on nataluzimab when compared to CRT in healthy controls.
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isolated from EAE C57/BL mice [17]. This may be due to
the fact that the antibody used to screen our tissue does
not discriminate between proteins encoded by spliced or
unspliced variants, or may reflect the differences betweenthe disease profile in our animal model and theirs. It is
most likely that translational arrest is occuring within cells
which stained positively for p-eIF2α, as phosphorylation
of this molecule is known to interfere with protein transla-
tion, as part of a well characterised self-protective
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misfolded proteins within the ER. It would be useful to de-
termine the duration of this molecular event and how tim-
ing of its appearance or disappearance within lesions
relates to tissue repair or ultimate cell and tissue
destruction.
It is likely that, when functioning within the ER, proteins
may have a role which differs to that found outside the
ER. For example, while in the ER lumen, CRT participates
in the CRT-calnexin cycle, ensuring correct folding of
glycosylated proteins and trafficking of mis-folded pro-
teins to the ER-associated degredation system. By an as
yet undefined means which may occur under conditions
of ER stress and may involve removal of the KDEL ER re-
tention sequence [7], CRT could be displayed on the cell
surface. This CRT cell surface expression may require
interaction with C1q complement and CD91 [21]. On the
other hand, given that EAE is a T cell-mediated disease, it
is also possible that CRT detected in the tissue samples
derived from our EAE rats, was released from granules
produced by invading cytotoxic T lymphocytes [22,23].
Whether originating from brain cells, or released from in-
vading T cells, CRT bound to C1q and CD91, may aid rec-
ognition and clearance of apoptotic cells by macrophages/
microglia [8]. Furthermore, some investigators have dem-
onstrated a direct interaction between phosphatidylserine
(PS) and CRT which was maintained when apoptosis
caused PS to be ‘flipped’ to the outer leaflet of the plasma
membrane [24,25]. It may be that CRT’s appearance at the
cell surface precedes PS exposure, as reported for tumour
cells [26]. Tarr et al also described ‘punctate clusters’
containing PS and CRT in apoptotic Jurkat T cells, remin-
iscent of the puctate staining seen in confocal imaging of
CRT-stained EAE lesions (Figure 4j). Intriguingly, there is
also a puncate quality to some of the CRT staining in the
ORO-CRT images reported here. Again, it is possible that
PS abnormally displayed on the outer surface of myelin
fragments could be bound by CRTas part of a myelin deb-
ris clearance process.
Once CRT is secreted into the circulation, it may func-
tion in modulating innate and adaptive immune responses.
In this regard, a large body of literature is accumulating on
the role of CRT in the pathogenesis of rheumatoid arthritis
(RA), another autoimmune disorder, Tarr et al [27] detected
significantly higher levels of extracellular CRT in the syn-
ovial fluid and plasma of rheumatoid arthritis patients. At
values between 232 and 623 ng/ml, the quantities of CRT
found in the serum of MS patients examined in our study,
were 20 to 30 times higher than those reported by Tarr et
al, leading to the speculation that circulating CRT could
also be playing a role in the pathogenesis of MS. Recent
descriptions that various proteins including Hsp70, BiP and
αB-crytstallin [28] have “chaperokine” functions suggest
that CRT could also be involved in determining the balancebetween peripheral pro- and anti-inflammatory T cell sub-
sets, although this remains to be definitively established.
Our finding that levels of circulating CRT in the serum
of EAE animals were significantly lower than levels
detected in control IFA and saline animals is challenging
to explain. Further time-course experiments need to
be carried out in rat and human cohorts, to determine
whether or not circulating CRT is, as we propose, a new
robust surrogate biomarker of demyelinating disease
and a possible ‘chaperokine’ in MS.
Conclusion
Through detection of significant changes in CRT expres-
sion in rat EAE tissue, we have highlighted the potential
importance of CRT as a mediator of MS pathogenesis.
Dual labelling of myelin fragments and CRT hints that
CRT could be involved in myelin clearance. Detection
of circulating CRT points to a possible role for this
chaperokine in regulating the profile of circulating immune
cells. This, together with our novel detection of significantly
altered levels of CHOP, CRT and eIF2α in EAE rat spinal
cord, highlights a need for the development of models
of ER stress which may be manipulated in the field of
MS research.
Methods
Expression and purification of MOG protein
Recombinant mouse MOG (rmMOG), corresponding to
the N-terminal Ig-like extracellular domain of mouse
MOG (amino acids 1 -116), was prepared as previously
described [29].
Animals
Female DA rats (Harlan, UK), weighing between 118-161 g,
were used for induction of spinal-cord demyelination. Food
and water were available ad libitum with light:dark cycles
12:12 in a temperature controlled room (20 ± 2°C), with
relative humidity of 45–70%. Animals were acclimatised for
one week prior to any experimental procedures. All animal
work presented in this paper was performed according to
the EU Directive 86/609 and the Cruelty to Animals Act
1876 enacted in Ireland by two Statutory Instruments: S.I
No 566/ 2002 and S. I. No 613/ 2005. Additionally and in
adherence to NUI Galway policies regarding research
involving live animals, this work was also authorised/
approved by National University of Ireland Galway Animal
Care and Research Ethics Committee (ACREC).
EAE induction, clinical evaluation and lesion
characterisation
Rats (n=10) were anaesthetised via inhalation anaesthesia
and injected intra-dermally into the dorsum base of the
tail with a total volume of 100 μl containing 25-50 μg
rmMOG (diluted in saline) emulsified in incomplete
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to previously described protocols [29,30]. Control animals
were similarly injected with a total volume of 100 μl IFA
(n = 5) or saline (n = 5). In this cohort, this protocol pro-
duced a relapsing-remitting disease course in the majority
of animals. Animals were weighed and the clinical level of
EAE was scored daily. Animals were assigned a clinical
score as follows: 0=no abnormality; 0.5= loss of tone in
the tip of the tail; 1 =flaccid tail; 2 =single hind-limb
paralysis; 3=double hind-limb paralysis; 4= quadriplegia;
5= moribund.
Mean clinical scores obtained in DA rats over a 43-day
period following intradermal injection of rmMOG are
depicted in Additional file 3a. Of 10 animals injected with
25 – 50 μg of rmMOG, 9 experienced paralysis at some
point during the 43-day period and clinical scores ranged
from 0.5 to 3. Remission was experienced in some animals,
leading to large standard deviations in clinical scores
(Additional file 3). Rats injected with IFA or saline alone
did not show clinical symptoms, in contrast to those
injected with MOG. A humoral response to MOG was also
detected in MOG-injected animals (Additional file 3b).
A representative image of the disappearance of MOG-
specific staining in the white matter of affected animals
is shown in Additional file 3c, contrasting with normal
MOG levels retained in control saline or IFA groups
(Additional file 3d and e). A macrophage-driven pathology
was confirmed as present in all lesions or absent in
controls, following immunofluorescent staining of large
numbers of cells for the macrophage / microglial-specific
marker IBA1 (Additional file 3f – h). Involvement of T
cells in pathology was also confirmed using antibiodies
to CD3 (Additional file 1). Myelin debris-laden areas
were also confirmed in demelinating lesions only, by
ORO staining (Additional file 3i-k).
Quantitative assessment of ER stress proteins was carried
out in 5 rats in which a demyelinating pathology had been
confirmed by loss reactivity to antibodies to MOG and by
loss of LFB staining. Lateral and ventral lesions incorporat-
ing GM regions were present in 4 out of 5 animals, while a
prominent dorsal lesion was detected in the fifth animal. It
was noted that the pathological features of the dorsal lesion,
in terms of infiltrating immune cells, did not differ to
features seen in lateral and ventral lesions. A demyelinating
pathology could not be detected in the remaining 5 an-
imals. It is possible that pathology was missed, as half
of the tissue collected was snap-frozen for use in RNA
isolation. For the reasons stated above, these individuals
were excluded from further analysis.
Measurement of humoral reactivity to MOG
To determine titres of anti-MOG antibody in serum,
bloods were collected via cardiac puncture following
termination and serum analysed by enzyme-linkedimmunosorbent assay (ELISA). Following clotting at 4°C,
serum was separated and collected following centrifugation
and stored at -20°C. Briefly, 10 μg / ml rmMOG was added
to 96-well plates (Sarstedt, Wexford, Ireland) and incubated
overnight at 4°C before blocking with 2% bovine serum
albumin (BSA; Sigma, Dublin, Ireland) in PBS for 1 h at
room temperature. The sera were diluted (1:400) in 1%
BSA / PBS and incubated for 2 h. Rat IgG–specific alkaline
phosphatase-linked secondary antibody (1:5000 in 1% BSA/
PBS; Sigma, Dublin, Ireland) was incubated for 1 h, prior to
detection with p-Nitrophenyl phosphate (Sigma, Dublin,
Ireland). The optical density was measured at 405 nm. All
incubations were at 37°C unless otherwise stated.Tissue harvesting and processing
Animals were sacrificed by CO2 asphyxiation 43 days post-
inoculation. Spinal cords (average length 80 mm) were cut
into 8 equally sized pieces. Each piece was further bisected,
with one piece being snap-frozen for RNA analysis and the
second used for histological analysis.Histological analysis and immunohistochemistry
All tissue for histology was fixed in freshly prepared 4%
paraformaldehyde overnight at 4°C and cryoprotected in
30% sucrose in PBS for 48 h. Tissue was then embedded
in OCT (VWR International Ltd, Dublin, Ireland) and
stored at -80°C. Histological evaluation was performed on
10 μm frozen sections which were thaw-mounted onto
Superfrost Plus slides (Fisher Scientific, Dublin, Ireland)
and stored at -80°C. Details of antibodies and conjugates
used for immunohistochemistry are shown in Table 1.Colorimetric immunohistochemistry
All sections were brought to room temperature, air-dried
and endogenous peroxidases blocked by incubation in 1%
hydrogen peroxidase in methanol. All primary antibodies
were incubated on sections at 4°C overnight, detected
using biotinylated secondary antibodies (see Table 1)
and ABC horseradish peroxidise-labelled Vectastain
Elite ABC reagent (Vector). Diaminobenzidine(DAB)
(Dako, Cambridgeshire, UK) was used as chromogen,
and all sections were counterstained in haematoxylin.Oil red O staining
Sections were brought to room temperature, air-dried
and incubated for 4 min in 60% ethanol. Slides were
incubated in Oil Red O (ORO; Sigma, Ireland) solution
(0.5% ORO in 60% ethanol) for 1 h at room temperature
and differentiated by rinsing in 60% ethanol and 4 washes
in water. After counterstaining in haematoxylin, slides were
mounted in gelatine mounting medium (in-house).
Table 1 Antibodies and conjugates used for immunohistochemistry
Antibody/Conjugate Isotype/Species Supplier Dilution
MOG Mouse mAb Prof R Reynolds, Imperial College London 1/100
BiP/GRP78 Rabbit pAb Abcam (ab32618) 1/100
CRT Mouse mAb Abcam (ab22683) 1/1000
CHOP/GADD153 Mouse mAb Cell signalling (L63F7) 1/200
CHOP/GADD153 Rabbit pAb Santa Cruz biotechnology (sc793) 1/200
p-EIF2a Rabbit mAb Cell signalling (119A11) 1/50
XBP1 Rabbit pAb Santa Cruz biotechnology (sc-7160) 1/100
Iba1 Rabbit pAb Wako (019-19741) 1/1000
GFAP Rabbit pAb Dako (Z0334) 1/1000
GFAP Mouse mAb Sigma (G3893) 1/500
Olig2 Mouse mAb Millipore (MABN50) 1/75
Olig2 Rabbit pAb Chemicon(AB9610) 1/65
NeuN Mouse mAb Millipore (MAB377) 1/1000
CD68 Mouse mAb Calbiochem (CB1014) 1/65
SMI32 Mouse mAb Abcam (ab28029) 1/1000
Biotinylated anti-rabbit Ig Swine pAb Dako (E0353) 1/400
Biotinylated anti-mouse Ig Rabbit pAb Dako (E0354) 1/400
Biotinylated anti-rabbit IgG (H&L) Goat pAb Vector (BA-1000) 1/200
Biotinylated anti-mouse IgG (H&L) Goat pAb Vector (BA-9200) 1/200
Alexafluor 488 anti-rabbit Goat pAb Invitrogen (A11008) 1/1000
Alexafluor 568 anti-rabbit Goat pAb Invitrogen (A11011) 1/1000
Alexafluor 488 anti-mouse Goat pAb Invitrogen (A11059) 1/1000
Alexafluor 568 anti-mouse Goat pAb Invitrogen (A11019) 1/1000
Fluorescein Avidin DCS n/a Vector (A-2011) 1/500
Cy3-conjugated streptavidin n/a Jackson Immuno Research 1/4000
Table 2 Clinical & demographic details of MS & control cases






(y)Duration (y) Last relapse Steroids (Y/N) Treatment
MS 11/11 M/33 3 RR 5 mo N Natalizumab C2/11 F/45
MS 16/11 F/33 1 RR 1 yr N Copaxone C4/11 F/28
MS 19/11 F/36 3 RR 3 yr N Copaxone C7/11 M/22
MS 24/11 F/32 12 RR 2 yr N Naltrexone C13/11 M/49
MS 31/11 M/49 3 RR 1 yr N Natalizumab C14/11 F/30
MS 32/11 F/44 22 RR 2.5 yr N Natalizumab C16/11 F/33
MS 33/11 F/39 12 RR 1 yr N Natalizumab C17/11 M/31
MS 35/11 F/24 6 RR 2 yr N Natalizumab C23/11 F/82
MS 36/11 F/33 10 RR 2 yr N Natalizumab C24/11 F/39
MS 38/11 F/46 13 RR 3.5 yr N Natalizumab C2/12 F/24
MS 39/11 M/33 6 RR 3.5 yr N Natalizumab C5/12 F/42
MS 41/11 M/29 3 RR 2 yr N Natalizumab
MS 44/11 F/58 22 RR/SP NK N Copaxone
MS 47/11 F/48 5 RR 5 yr N Rebif
Key: mo months, yr years, NK not known.
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Double-staining for CRT and ORO was carried out
by firstly performing standard immunohistochemistry
(as described above), prior to counterstaining in haema-
toxylin and staining with ORO (as described above).
Immunofluorescent double-staining
All sections were brought to room temperature, air-dried,
washed in PBS/0.05% Triton-X-100 and incubated in
ice-cold methanol for 10 min. All sections were blocked
in 5% normal goat serum (NGS) for 1 h and incubated
overnight with primary antibody diluted in 1% NGS/1%
BSA. Antibodies were visualised using the relevant
Alexafluor conjugates (see Table 1) and all slides mounted
in Vectashield containing diamino-2-phenylindole (DAPI)
(Vector) to allow visualisation of nuclei.
Prior to carrying out confocal analysis of dual-labelled
tissue, signal from one of the primary antibodies was
amplified. Staining was done as described above, except
a biotinylated primary antibody was used, followed by an
appropriate secondary antibody (see Table 1 for details).
Imaging
UV microscopy images were acquired using Olympus BX51
Upright Fluorescent Microscope (Olympus, Dublin, Ireland)
with Improvision Optigrid System, or an Olympus IX81
Fluorescent Microscope, together with Improvision
Volocity software (PerkinElmer, Dublin, Ireland). Confocal
analysis was done using a Zeiss LSM 510 Axiovert Inverted
Confocal Microscope (Carl Zeiss).
Semiquantitative scoring of tissue staining
Expression of BiP, CHOP, XBP1, p-eIF2α and CRT was
assessed in the lesion (L) and lesion edge (LE). It was
also noted whether there was positive staining of ER
stress-associated molecules in the grey matter (GM),
the central canal (CC) and normal appearing white
matter (NAWM) adjacent to lesioned WM. Scoring of
immunostaining was carried out using a graded scale,
ranging from 0.5– 4. Scores were assigned as follows:
0.5=minimal positive staining; 1=small numbers of
positive cells in the white matter; 2=moderate number
of positive cells 3=moderately high numbers of positive
cells; 4=high numbers of positive cells.
Calreticulin ELISA
Serum levels of CRT were determined by ELISA following
the manufacturer’s instructions (USCNK, Life Science Inc,
Wuhan, China; catalogue number E91486Hu, for human
samples; catalogue number CSB-E14943r for rat samples).
Rat serum samples analysed for MOG reactivity were also
assayed for expression of circulating CRT.
Clinical details of MS patients sampled for analysis of
circulating CRT, including age, disease duration, treatmentand time since last relapse are provided in Table 2. A sum-
mary of relevant information from age-matched controls is
given in the same table.
Statistical analysis
Differences in data sets were determined using analysis
of variance (ANOVA) or Student’s t-tests. Real time PCR
data was analysed by a one-way ANOVA. Differences in
ER stress ELISA data sets were calculated using Newman-
Keuls multiple comparisons test whereas Dunn’s post-test
was used to evaluate differences for the MOG ELISA data
set. Differences in ER stress expression in spinal cord tissue
following semi-quantitative analysis was completed with a
Kruskal-Wallis test followed by a Dunn’s post test, using
GraphPad Prism software (San Diego, Ca, USA). All data
were expressed as mean and the standard error of the mean
(SEM). Differences were deemed significant if p < 0.05.
Additional files
Additional file 1: CD3 and CRT staining in EAE spinal cord.
Immunofluorescent labelling of T cells (a) within a demyelinated lesion,
using CD3 antibody (Abcam ab5690) incubated overnight at 4°C. After
washing and re-probing with fluorescently-tagged anti-rabbit secondary
antibody, positively stained T cells were detected (green). Dual labelling
of grey matter in EAE sample spinal cord tissue (b) demonstrated
localisation of CHOP in neurons staining positively for NeuN (arrow). The
same protocol used for CD3 staining was followed for fluorescent CHOP
(Santa Cruz, Sc793) and NeuN (Millipore MAB377) staining. Staining
obtained in the absence of primary body, but the presence of anti-rabbit
(c) or anti-mouse (d) secondary antibody is shown. Scale bars = 500 μm
(a, c, d) or 50 μm (b).
Additional file 2: CRT expression in MS spinal cord tissue. Snap-frozen
human spinal cord tissue was isolated after a 22 h postmortem delay, from
a male who suffered from secondary progressive MS and died at the age of
45 following a disease duration of 15 years. Staining with MOG antibody
(hybridoma supernatant from Reynolds lab) detected using biotinylated
HRP-labelled anti-mouse secondary antibody and DAB chromogenic
substrate, revealed a loss of MOG expression, consistent with a lateral lesion
(dotted black line, L, a). Following the same protocol to that used for MOG
staining, a serial section was stained for CRT using Abcam ab22683
antibody. Positive staining for CRT was found within the lateral lesion (b). At
higher magnification, co-localisation of CRT in or at the rim of Oil Red
O-stained myelin fragments was seen (c and d). Scale bars: 500 μm (a-b);
50 μm (c and d). MS tissue was supplied by the UK Multiple Sclerosis Tissue
Bank, funded by the Multiple Sclerosis Society of Great Britain and Northern
Ireland, registered charity 207495.
Additional file 3: Clinical scores, humoral response and spinal cord
demyelination following induction of EAE. Clinical signs of paralysis
were monitored daily (a) following EAE induction. Blood samples were
taken following sacrifice and a MOG ELSIA conducted to assess the level
of MOG antibodies in the serum. Serum from animals immunised with
rmMOG had a significantly higher antibody response than control groups
(b). Data are expressed as mean ± SEM. Representative spinal cord
neuropathology (43 days post immunisation) with demyelination and
infiltrating inflammatory cells (by haematoxylin counterstaining) in
lesioned areas (c) in DA rats immunized with MOG emulsified in IFA.
Intact myelin is seen in the spinal cord white matter of saline- and
IFA- injected control rats (“control”; score = 0; d & e). Immunofluorescent
double-staining for MOG (red) and microglia/macrophage (Iba1; green)
(f-h) shows that demyelination is accompanied by macrophage/
microglial infiltration of the lesioned area (f). Few Iba1+ cells are present
in control animals (g and h).Tissue from saline- and IFA-injected animals
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lipid staining in EAE lesions (i) indicating the presence of foamy
macrophages. Scale bars = 100 μm (c-h) and 50 μm (i-k).
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